The expansion of the partnership with Mark Cuban Cost Plus Drugs Company is likely to reduce medication costs for CHS-affiliated hospitals, potentially improving their financial performance and patient satisfaction. This positive development is expected to have a favorable short-term impact on CYH's stock price.